| Journal | Journal of psychiatric research |
| Study Type | Clinical Study |
| Population | Human participants |
This item covers developments relevant to cannabis medicine and clinical practice. Clinicians monitoring evidence in this area should review the source material.
Cannabis use is associated with psychosis development and symptom relapse in persons with schizophrenia spectrum disorders (SCZ). As U.S. states legalize cannabis and products increase in potency, it is crucial to better understand recent cannabis use patterns in SCZ. We conducted a scoping review of research on cannabis quantity, frequency, or type in SCZ after January 2016 and present a case series of cannabis use in inpatients with psychosis (2023-2024). Scoping review: Of 672 references, ten studies (2631 participants) were included; none were designed to characterize cannabis quantity, frequency, or type of use over time. Cannabis measurement methodology varied; most studies did not use standardized measures. Frequency and quantity of use at baseline were reported by most studies and these ranged widely. At least a minority of participants with SCZ in each study used cannabis very frequently; quantity of used ranged widely from 0.6 ± 0.6 to 3.4 ± 2.2 joints/day. One small study de
“This is a development worth tracking. The clinical implications will become clearer as more evidence accumulates.”
💬 Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
Have thoughts on this? Share it:
FAQ
This study item was assembled from normalized source metadata and pipeline scoring.
